Q-omics provides the consensus-scored PRDM14 profile across patient tissues and cancer cell-line models. PRDM14 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, PRDM14 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, PRDM14 RNA expression shows 7,801 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, KIRP, and TGCT as cancer lineages where PRDM14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM14 survival associations across molecular data types. PRDM14 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM14 RNA expression–survival associations across cancer types. High PRDM14 expression shows unfavorable associations in OV, LIHC, CHOL, SCLC, MESO and READ. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify OV as the clearest survival context for PRDM14 RNA expression.
This table summarizes PRDM14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRDM14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM14 shows lower tumor expression in KIRP, KIRC and KICH and higher tumor expression in UCEC, LUAD and THCA. The KIRP box plot shows higher PRDM14 RNA expression in normal versus tumor tissue (log2 FC = −0.226, t-test p = .036).
This table shows molecular features associated with PRDM14 in patient tissues and cancer cell lines. In patient samples, PRDM14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
